{"id":"W2891759256","doi":"10.1200/jco.2017.35.15_suppl.7503","title":"A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Chemoimmunotherapy; Fludarabine; Internal medicine; Chronic lymphocytic leukemia; Rituximab; Cyclophosphamide; Obinutuzumab; Gastroenterology; Randomized controlled trial; Interim analysis; Regimen; IGHV@; Lenalidomide; Oncology; Leukemia; Surgery; Multiple myeloma; Chemotherapy; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003416318,0.002179134,0.002135648,0.0007031029,0.0005858366,0.0008142627,0.001000777,0.002153371,0.00467871],"category_scores_gemma":[0.002418023,0.0008148949,0.00162595,0.0006057523,0.001172032,0.0006720498,0.0004986188,0.002452702,0.0008214668],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001210207,"about_ca_system_score_gemma":0.002470898,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001525296,"about_ca_topic_score_gemma":0.003466106,"domain_scores_codex":[0.9984728,0.0009914259,0.00006269961,0.0001964717,0.0001014806,0.0001751044],"domain_scores_gemma":[0.9986503,0.0002952158,0.0002895322,0.0001304258,0.0000763386,0.00055827],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9643628,0.0159928,0.002938364,0.0001431305,0.0007918935,0.00005540626,0.00005951745,0.0004579102,0.004234612,0.00007794289,0.0008496891,0.01003608],"study_design_scores_gemma":[0.9313245,0.06307019,0.004143783,0.00000982651,0.00036508,0.00002888084,0.00001197309,0.0002426602,0.0002526602,0.000111475,0.000427409,0.00001167537],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915197,0.001005572,0.0005483166,0.0006049419,0.0001566748,0.003979652,0.001268632,0.00007156919,0.0008448819],"genre_scores_gemma":[0.9770814,0.001058062,0.003285951,0.002333005,0.0003666533,0.01029892,0.002929127,0.00004094864,0.002605935],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00467871,"threshold_uncertainty_score":0.01806742,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07279910882673507,"score_gpt":0.4713194874257098,"score_spread":0.3985203785989747,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}